Treatment of locally advanced renal tumors

被引:1
作者
Sanchez Zalabardo, D. [1 ]
Millan Serrano, J. A. [1 ]
De Pablo Cardenas, A. [1 ]
Cuesta Alcala, J. A. [1 ]
机构
[1] Hosp Rema Sofia, Serv Urol, Navarra, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2010年 / 34卷 / 02期
关键词
Locally advanced renal tumor; Treatment; Tyrosine kinase inhibitors; Sunitinib; Sorafenib; Tersirolimus; Bevacizumab; LYMPH-NODE DISSECTION; CELL CARCINOMA; RADICAL NEPHRECTOMY; RANDOMIZED-TRIAL; PHASE-III; THERAPY; CANCER; INVOLVEMENT; INVASION; PROTOCOL;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Locally advanced renal tumors show a high progression rate after surgery. Surgical treatment of renal tumors has some unique characteristics related to involvement of the adrenal gland, vena cava, or regional lymph nodes. Objective: To review the current treatment of locally advanced renal tumors. Materials and methods: A review is made of both the different drugs used and the different therapeutic possibilities in these tumors. Results: Systemic treatment with angiogenesis inhibitors may improve the natural history of these patients. Systemic treatment may be administered before surgery or as an adjuvant to surgical treatment. Early studies showed a decrease in tumor mass when treatment is administered before surgery, but no prospective randomized studies providing adequate evidence for recommending neoadjuvant treatment are available. Conclusions: Availability of systemic treatment with angiogenesis inhibitors may open an important field in the treatment of these tumors in both the neoadjuvant setting and as adjuvants to surgery, but no sufficiently solid scientific evidence as to recommend their use is currently available. Randomized studies with sunitinib and sorafenib will probably suggest the adequate approach to be used when their final results are reported. (C) 2009 AEU. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:134 / 141
页数:8
相关论文
共 50 条
  • [41] Systemic treatment of patients wish advanced hepatocellular carcinoma
    Potemski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2021, 17 (04): : 164 - 168
  • [42] AxitinibIn Advanced, Treatment-Experienced Renal Cell Carcinoma
    Lily P. H. Yang
    Kate McKeage
    Drugs, 2012, 72 : 2375 - 2384
  • [43] Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal?
    Eng, Cathy
    Crane, Christopher H.
    Rodriguez-Bigas, Miguel A.
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2009, 6 (01): : 16 - 17
  • [44] External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors
    Cuaron, John J.
    Goodman, Karyn A.
    Lee, Nancy
    Wu, Abraham J.
    RADIATION ONCOLOGY, 2013, 8
  • [45] Regorafenib for treatment of advanced gastrointestinal stromal tumors
    Overton, Lindsay C.
    Heinrich, Michael C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (04) : 549 - 558
  • [46] Current Treatment Options for Disseminated Renal Cell Carcinoma
    Waalkes, Sandra
    Schrader, Andres J.
    Kuczyk, Marcus A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (03) : 73 - 78
  • [47] Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, Beate
    Neumann, Henrike
    Roy, Renee
    Heuer, Vera
    Kummer, Gerhard
    Strumberg, Dirk
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (01) : 72 - 73
  • [48] Efficacy and Toxicity of Doxorubicin and Cyclophosphamide for the Neoadjuvant Treatment of Locally Advanced Stage Canine Mammary Tumors
    Kuruoglu, Fikriye Ecem
    Ozyigit, Musa Ozgur
    Nak, Deniz
    Kupeli, Zehra Avci
    Ekici, Zeynep Merve
    Koca, Davut
    Avcilar, Talha
    Sahin, Mustafa Eren
    Nak, Yavuz
    Shahzad, Abid Hussain
    KAFKAS UNIVERSITESI VETERINER FAKULTESI DERGISI, 2020, 26 (06) : 729 - 734
  • [49] COMPLEX TREATMENT OF LOCALLY ADVANCED MALIGNANT TUMORS OF THE THYROID GLAND WITH INVASION INTO THE ORGANS OF THE NECK AND MEDIASTINUM
    Deineko, I. V.
    WORLD OF MEDICINE AND BIOLOGY, 2024, 88 (02): : 53 - 58
  • [50] Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
    Negrier, Sylvie
    Perol, David
    Bahleda, Rastislav
    Hollebecque, Antoine
    Chatelut, Etienne
    Boyle, Helen
    Cassier, Philippe
    Metzger, Sevrine
    Blanc, Ellen
    Soria, Jean-Charles
    Escudier, Bernard
    BMC CANCER, 2017, 17